Analysis of the clinical application of Opicapone in treating “on-off” phenomenon

Opicapone is a third-generation catechol-O-methyltransferase (COMT) inhibitor. It is mainly used for adjuvant treatment of patients with Parkinson's disease, especially in dealing with the "on-off" phenomenon. It shows good clinical value. The "on-off" phenomenon means that after a patient takes levodopa for a period of time, the efficacy of the drug fluctuates significantly, and motor symptoms suddenly improve ("on") and worsen ("off") alternately, seriously affecting the quality of life.

Opicapone inhibits peripheral COMT activity and delays the metabolism of levodopa, thereby extending its half-life and effective time in the body, helping to stabilize blood concentration and reduce the frequency and duration of the "off" period. Compared with early COMT inhibitors such as tolcapone, opicapone has a longer action time and better tolerability. It only needs to be taken once a day, making it easier for patients to insist on long-term use, and the risk of hepatotoxicity is significantly reduced.

Clinical studies have shown that in patients with Parkinson's disease treated with Opicapone, their "off" period can be reduced by about 1 on average by more than 1 hours, and the adverse reactions are generally controllable. The most common adverse events include mild aggravation of dyskinesia and hallucinations. The addition of opicapone may also eliminate the need for a significant increase in the original total dose of levodopa, further reducing the risk of drug-related side effects.

In general, as a new, long-acting and highly safe COMT inhibitor, opicapone has significant clinical significance in the management of "on--off" fluctuations in Parkinson's disease. For patients who experience fluctuations in drug efficacy, especially those who have taken drugs regularly but still have significant fluctuations in symptoms, Opicapone can be an important option to optimize the treatment plan. Rational application of this drug is expected to improve patients' motor control ability and quality of life.

Reference materials:https://www.ongentys.com/